年龄相关性黄斑病变新兴药物的治疗进展  

Advances in Emerging Pharmacologic Therapies for Age-related Macular Degeneration

作　　者：郑贤何[1,2] 谢伯林[1] 

机构地区：[1]成都军区昆明总医院眼科,昆明650032 [2]昆明医科大学成都军区昆明总医院临床学院,昆明650031

出　　处：《医学综述》2013年第6期1075-1077,共3页Medical Recapitulate

基　　金：云南省自然科学基金(2010ZC178)

摘　　要：年龄相关性黄斑病变(AMD)是发达国家老年人首位的致盲眼病。在我国,由于人口的老龄化,AMD发病率也呈上升趋势,因此需正确深入认识此病并且采取有效的治疗措施。AMD在临床上分为萎缩性和渗出性,虽然渗出性发病率低,但对患者的视力危害极大,主要表现为脉络膜新生血管(CNV)及黄斑部出血、渗出。相关学者开始在这些复杂的病理生理过程中寻找定位于多靶点的、不同作用机制的新的因子。目前,很多药物治疗研究已被证实能够成功减少因AMD造成的视力下降,并有可能取得进一步发展的潜力。Age-related macular degeneration（AMD）is defined as a disease that leads to severe visual loss and legal blindness specially in the developed countries.In China,as the incidence of AMD increased year by year with the aging of population,it is stringent to understand the mechanism and to investigate the effective treatments.AMD is clinically categorized into wet AMD and atrophic AMD.As the severer type,wet AMD leads to the severe damage to eyes,including choroid neovascularization（CNV）,macula hemorrhage and exudation,though the incidence is lower than atrophic.Researchers were exploring new agents with different mechanisms of action addressing multiple targets in this complex pathophysiology.Here is to make a review on the emerging agents which have been demonstrated to successfully decrease the AMD caused visual loss and briefly discuss the next step for the treatment of AMD.

关 键 词：年龄相关性黄斑病变 治疗 脉络膜新生血管 

分 类 号：R773.4[医药卫生—眼科]